AI Image
Moderna CEO on what's next after success in cancer vaccine
STAT • • business
Key Points:
- Moderna CEO Stéphane Bancel expressed great satisfaction as the company prepared to present successful Phase 3 trial results for intismeran, a customized mRNA therapy for melanoma.
- The therapy, developed over a decade with Merck, demonstrated improved outcomes for melanoma patients, marking a significant milestone in cancer treatment.
- Bancel highlighted the skepticism in the field regarding cancer vaccines but emphasized Moderna's conviction and collaborative effort in achieving this breakthrough.
- The announcement took place at the European Society for Medical Oncology annual meeting in Madrid, underscoring the therapy's potential impact on oncology.
